Miromatrix | Leaders in Biomedical Engineering Organs

Miromatrix was created to bring our vision of a world without an organ transplant waitlist to life. With an average of 17 people dying each day waiting for a life-saving organ, the need for a solution is more critical than ever.

Founded in 2009 from the University of Minnesota's breakthrough advances in perfusion decellularization and recellularization technology, we are the world leader in the research and development of fully biologic organs. Our approach is expected to be an efficient way to answer the unmet need of thousands of patients across the country who will otherwise go without the transplant they need to survive and thrive.

Miromatrix has 140 issued patents worldwide. Our technology has the potential to be applied across the spectrum of donor needs. We are focused on the research and development of transplantable kidneys (mirokidney^®), livers (miroliver^®), and a bioengineered external liver assist device for acute liver failure (miroliverELAP^®), with plans to also bioengineer other critical organs like lungs, pancreases and hearts.

Our decellularization technology is supported through extensive pre-clinical and clinical data with our previously commercialized FDA cleared matrix products. The promise of our recellularization technology is supported through extensive pre-clinical studies and we received IND clearance to begin clinical investigations of miroliverELAP^®.

Nature holds the key to the future of regenerative medicine, and we are excited to continue to harness its potential.